5(Z)-5-(6-Quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
AssigneeGlaxoSmithKline LLC
InventorsKevin Duffy, Duke Fitch, Beth Norton
Life of this patent
Estimating the term…
Abstract
Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.
Claims29
A compound comprising (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H-one, and/or a pharmaceutically acceptable salt, a hydrate, a solvate, and a pro-drug thereof.
A compound comprising (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H-one meglumine, and/or a pharmaceutically acceptable hydrate, and a solvate thereof.
Dependencies are inferred from the claim text.